Skip to main content
Terug
CSWYF logo

China Shineway Pharmaceutical Group Limited

Datakwaliteit: 100%
Overbought
CSWYF
OTC Healthcare Drug Manufacturers - Specialty & Generic
€ 1,00
€ 0,00 (0,00%)
Marktkapitalisatie: 758,42M
Dagbereik
€ 0,93 € 1,00
52-Weeksbereik
€ 0,93 € 1,00
Volume
100
50D / 200D Gem.
€ 1,00 / € 1,00
Vorige Slotkoers
€ 1,00

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E 0,9 0,4
P/B 0,1 2,9
ROE % 19,9 3,7
Net Margin % 22,2 3,8
Rev Growth 5Y % 77,0 10,0
D/E 0,1 0,2

Belangrijkste Punten

Revenue grew 77,01% annually over 5 years — strong growth
Earnings grew 512,46% over the past year
ROE of 19,86% — decent returns on equity
Net margin of 22,24% shows strong profitability
Debt/Equity of 0,05 — conservative balance sheet
Generating 823,02M in free cash flow

Groei

Revenue Growth (5Y)
77,01%
Revenue (1Y)-16,35%
Earnings (1Y)512,46%
FCF Growth (3Y)127,31%

Kwaliteit

Return on Equity
19,86%
ROIC8,09%
Net Margin22,24%
Op. Margin22,30%

Veiligheid

Debt / Equity
0,05
Current Ratio3,51
Interest Coverage137,48

Waardering

P/E Ratio
0,90
P/B Ratio0,10
EV/EBITDA-5,98
Dividend Yield0,54%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -16,35% Revenue Growth (3Y) 153,46%
Earnings Growth (1Y) 512,46% Earnings Growth (3Y) 179,42%
Revenue Growth (5Y) 77,01% Earnings Growth (5Y) 110,54%
Profitability
Revenue (TTM) 3,78B Net Income (TTM) 840,05M
ROE 19,86% ROA 8,37%
Gross Margin 74,95% Operating Margin 22,30%
Net Margin 22,24% Free Cash Flow (TTM) 823,02M
ROIC 8,09% FCF Growth (3Y) 127,31%
Safety
Debt / Equity 0,05 Current Ratio 3,51
Interest Coverage 137,48 Dividend Yield 0,54%
Valuation
P/E Ratio 0,90 P/B Ratio 0,10
P/S Ratio 0,20 PEG Ratio 0,00
EV/EBITDA -5,98 Dividend Yield 0,54%
Market Cap 758,42M Enterprise Value -5,04B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 3,78B 4,52B 588,09M 498,18M 384,87M
Net Income 840,05M 137,16M 107,59M 86,03M 42,76M
EPS (Diluted) 1,11 0,18 0,14 0,11 0,06
Gross Profit 2,83B 3,39B 437,40M 372,50M 288,08M
Operating Income 842,60M 975,54M 106,22M 82,58M 61,21M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 10,04B 1,35B 1,18B 1,13B 1,10B
Total Liabilities 2,57B 357,93M 265,79M 177,39M 185,79M
Shareholders' Equity 7,47B 991,63M 917,31M 925,70M 885,99M
Total Debt 346,53M 301,33M 1,07M 2,34M 59,96M
Cash & Equivalents 6,14B 5,89B 725,29M 659,71M 648,80M
Current Assets 8,60B 8,15B 974,78M 893,96M 843,92M
Current Liabilities 2,45B 2,43B 239,38M 172,29M 182,68M

Strategiescores

This stock passed the criteria for 3 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#732 of 820
19
Custom Contrarian Investing (David Dreman)
#491 of 658
14
Value Defensive Investing (Benjamin Graham)
#482 of 708
19

Recente Activiteit

Ingestapt Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt Contrarian Investing (David Dreman)
Mar 24, 2026
Ingestapt Defensive Investing (Benjamin Graham)
Mar 24, 2026